[ad_1]
The Wall Street Journal (WSJ) reported on Thursday (3) that due to supply chain challenges, Pfizer (PFE-US) revised its new corona vaccine production target by half this year to 50 million. dose. Pfizer’s stock price fell 1.7%. Moderna (MRNA-US) said the research results show that their immunity to the vaccine is long-lasting and can last for three months.
Pfizer and BioNTech (BNTX-US), a German company that makes vaccines, originally planned to supply around 100 million doses of vaccines by the end of the year, but has now cut half to 50 million doses. Since a single course of treatment requires two doses, the representative will provide the treatment to approximately 25 million people.
A Pfizer spokesman said it took longer than expected to expand the raw material supply chain and the time for the clinical trial results to be published was slower than expected. However, he also added that the production line has been overhauled and the vaccine is being produced rapidly.
According to the WSJ report, anonymous individuals involved in vaccine development revealed that some of the raw materials collected at the initial stage did not meet the standards, causing production delays.
Bad news from Pfizer’s supply chain caused US stocks to turn from red to black at the end of trading, while Pfizer fell 1.74% in the last session and 0.3% in the following hours of trading. negotiation.
Pfizer applied for an emergency use authorization (US) from the US regulatory agency in November. Approval is expected to be obtained this month. The first batch of vaccines distributed by the US government will contain 6.4 million doses, with the number increasing later. British regulators have approved the use of the Pfizer vaccine.
Moderna claims the vaccine has long-lasting immunity
On the other hand, Moderna announced that the new corona vaccine has the potential to achieve longer-term immunity and it is estimated that 20 million doses of vaccine can be delivered in the United States this year. Moderna’s shares rose nearly 10% at the end of Thursday, but fell 1.3% after the market.
According to Moderna, according to research from the National Institute of Allergy and Infectious Diseases (NIAID), the subjects who participated in the initial trial maintained their antibodies at a high level for three months after the first dose of the vaccine (for those who received the second dose) Held for two months), showing that this vaccine “has the potential to provide long-lasting immunity”, and there are no serious adverse reactions after two months.
Moderna said in a statement that these interim data from the first phase show that the company’s new corona mRNA-1273 vaccine can produce durable neutralizing antibodies for all age groups, including the elderly.
Moderna said she is confident that 20 million doses of vaccines will be provided in the United States by the end of the year. 100 million to 125 million doses are expected to be delivered globally in the first quarter of next year, of which 85 million to 100 million doses will be delivered to the United States.
[ad_2]
